FDA sanctions new version of Essure:
This article was originally published in Clinica
Executive Summary
A third-generation Essure permanent birth control system developed by Conceptus has gained approval from the US FDA. Conceptus says that the new version is superior to previous models due to its revamped delivery system, which has reduced the number of steps a physician must take when placing the device in the patient's fallopian tubes. In addition to being simpler to implant, the hysteroscopic visualisation of the implant and placement markers have also been improved, and a new DryFlow Introducer, which alleviates distension fluid loss, is being packaged with the product. The Essure procedure is the only FDA-approved female sterilisation procedure to prevent 100% of pregnancies in clinical trials, said the Mountain View, California firm.